Drug firm Divi’s Laboratories on Saturday reported a 16.71 per cent jump in its consolidated net profit at Rs 606.46 crore for the quarter ended September 30, mainly on account of robust sales.
The company had posted a net profit of Rs 519.59 crore for the corresponding period of the previous fiscal, Divi’s Laboratories said in a filing to the BSE.
Its consolidated total income during July-September 2021 stood at Rs 2,006.62 crore. It was Rs 1,762.94 crore in the year-ago period, it added.
The group has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to the Covid-19 pandemic, Divi’s Labs said.
Suven Pharma
Suven Pharmaceuticals on Saturday posted a 31 per cent increase in its consolidated net profit at Rs 97 crore for the second quarter ended September 30. The company had reported a net profit of Rs 74 crore in the July-September period of the previous fiscal. Revenue from operations rose to Rs 301 crore.